TABLE 4.
Univariate |
Multivariate |
|||
HR (95% CI) | P-value | HR (95% CI) | P-value | |
MACE | ||||
Big ET-1* | 1.85 (1.26–2.72) | 0.002 | 2.05 (1.36–3.09) | 0.001 |
Big ET-1 tertile 1 | Reference | – | Reference | – |
Big ET-1 tertile 2 | 1.35 (0.59–3.09) | 0.477 | 1.24 (0.51–3.05) | 0.634 |
Big ET-1 tertile 3 | 2.32 (1.09–4.92) | 0.029 | 2.60 (1.16–5.81) | 0.02 |
Secondary endpoints | ||||
Big ET-1* | 1.77 (1.19–2.63) | 0.005 | 1.98 (1.29–3.03) | 0.002 |
Big ET-1 tertile 1 | Reference | – | Reference | – |
Big ET-1 tertile 2 | 1.06 (0.46–2.43) | 0.893 | 0.97 (0.40–2.37) | 0.948 |
Big ET-1 tertile 3 | 1.93 (0.93–4.04) | 0.079 | 2.00 (0.91–4.41) | 0.084 |
*Big endothelin-1 (ET-1) was natural log-transformed. Major adverse cardiovascular events (MACE) model adjusted for age, sex, angulated lesion, history of coronary artery bypass grafting [CABG], low-density lipoprotein cholesterol [LDL-c], reference vessel diameter, thyroid disease. Secondary end points model adjusted for age, sex, angulated lesion, history of CABG, early ISR, and non-ISR lesion intervention.